Stock SQZB SQZ BIOT
Add to a list
To use this feature you must be a member
Log inSign up

Financials SQZ BIOT OTC Markets

Equities

SQZB

US78472W1045

Biotechnology & Medical Research

Delayed OTC Markets
Other stock markets
 18:40:00 01/05/2024 BST 		5-day change 1st Jan Change
0.0499 USD +7.31% Intraday chart for SQZ BIOT +7.31% +150.75%
02-29 STEMCELL Technologies Canada Inc. completed the acquisition of substantially all of the assets of SQZ Biotechnologies Company. CI
2023 STEMCELL Technologies Canada Inc. entered into an asset purchase agreement to acquire substantially all of the assets of SQZ Biotechnologies Company for $11.8 million. CI

Valuation

Fiscal Period: December 2020 2021 2022
Capitalization 1 716.3 250.6 21.79
Enterprise Value (EV) 1 593 176.8 -14.44
P/E ratio -3.1 x -3.58 x -0.27 x
Yield - - -
Capitalization / Revenue 34.1 x 9.25 x 1.01 x
EV / Revenue 28.2 x 6.53 x -0.67 x
EV / EBITDA -11.9 x -2.62 x 0.19 x
EV / FCF -44,464,631 x -4,604,375 x 430,068 x
FCF Yield -0% -0% 0%
Price to Book 5.65 x 2.03 x 0.38 x
Nbr of stocks (in thousands) 24,717 28,067 29,451
Reference price 2 28.98 8.930 0.7400
Announcement Date 18/03/21 16/03/22 22/03/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022
Net sales 1 12.67 20.11 21 27.1 21.48
EBITDA 1 -19.34 -32.88 -49.72 -67.56 -74.32
EBIT 1 -20.4 -34.26 -51.06 -68.77 -75.82
Operating Margin -161.05% -170.4% -243.16% -253.78% -353.04%
Earnings before Tax (EBT) 1 -20.23 -32.2 -50.52 -68.74 -79.46
Net income 1 -20.23 -32.2 -50.52 -68.74 -79.46
Net margin -159.71% -160.14% -240.6% -253.68% -369.98%
EPS 2 -13.43 -19.89 -9.352 -2.493 -2.758
Free Cash Flow - -11.25 -13.34 -38.4 -33.59
FCF margin - -55.93% -63.52% -141.71% -156.38%
FCF Conversion (EBITDA) - - - - -
FCF Conversion (Net income) - - - - -
Dividend per Share - - - - -
Announcement Date 09/10/20 09/10/20 18/03/21 16/03/22 22/03/23
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3
Net sales 1 4.539 4.755 12.35 2.869 3.215 3.452 11.94 - 0.178 -
EBITDA -18.76 -22.16 - - - - - - - -
EBIT 1 -19.08 -22.46 -11.83 -21.05 -22.5 -23.1 -9.17 -18.26 -17.11 -23.8
Operating Margin -420.27% -472.26% -95.8% -733.81% -699.94% -669.12% -76.78% - -9,611.24% -
Earnings before Tax (EBT) 1 -19.07 -22.45 -11.82 -21.04 -22.24 -22.64 -13.55 -17.69 -16.77 -23.64
Net income 1 -19.07 -22.45 -11.82 -21.04 -22.24 -22.64 -13.55 -17.69 -16.77 -23.64
Net margin -420.14% -472.13% -95.72% -733.29% -691.63% -655.94% -113.43% - -9,421.35% -
EPS 2 -6.800 -8.000 -4.100 -7.500 -7.800 -7.700 -4.600 -6.000 -0.5700 -0.8000
Dividend per Share - - - - - - - - - -
Announcement Date 04/08/21 10/11/21 16/03/22 10/05/22 04/08/22 09/11/22 22/03/23 10/05/23 10/08/23 08/11/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022
Net Debt 1 - - - - -
Net Cash position 1 107 56 123 73.8 36.2
Leverage (Debt/EBITDA) - - - - -
Free Cash Flow - -11.2 -13.3 -38.4 -33.6
ROE (net income / shareholders' equity) - -53% -54.4% -54.7% -87.7%
ROA (Net income/ Total Assets) - -16% -16.6% -18.8% -29.1%
Assets 1 - 201.4 303.6 365.7 273.4
Book Value Per Share 2 -27.10 -44.60 5.130 4.410 1.940
Cash Flow per Share 2 37.10 23.80 6.870 5.100 2.160
Capex 1 1.31 2.17 1.18 0.61 0.52
Capex / Sales 10.3% 10.78% 5.61% 2.26% 2.43%
Announcement Date 09/10/20 09/10/20 18/03/21 16/03/22 22/03/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MODERNA, INC. Stock Moderna, Inc.
+22.10% 42.68B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.56% 42.4B
LONZA GROUP AG Stock Lonza Group AG
+45.32% 40.04B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 28.31B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.39% 24.94B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-19.97% 18.96B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.72% 12.3B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-2.87% 11.95B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
-2.37% 11.55B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. SQZB Stock
  4. SQZB Stock
  5. Financials SQZ BIOT